"Promising AI-Developed COVID Drug Advances to Phase I Trials, Targets All Variants"
Insilico Medicine, an AI-driven biotech company, has announced that its AI-designed drug for COVID-19 has entered Phase I clinical trials. The oral drug, if approved, would become the first-ever alternative to Paxlovid and has shown effectiveness against all variants of the virus. It is also more stable and works for a longer period of time compared to Paxlovid. The new drug is easy to produce in large quantities and is currently being evaluated for safety and tolerability in healthy volunteers. The results of the clinical trials are expected to be released by the end of 2023.